Steven Cohen’s Immunome IMNM Stock Holding History

Steven Cohen’s Portfolio IMNM Stock Details IMNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-75,000	Closed	-$1.61M	–	4121
2025 Q4	$1.61M	Buy	+75,000	New	+$1.32M	﹤0.01%	2605

Other funds holding IMNM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Steven Cohen's IMNM Position: Q1 2026 in Review

Steven Cohen sold out of Immunome (IMNM) in Q1 2026, closing a stake of 7,034,952 shares — an estimated $151M sold.

Steven Cohen first reported a position in IMNM in Q2 2023 and held it in 11 quarters. The position peaked at $151M in Q4 2025. 201 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

Steven Cohen reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
Steven Cohen sold 7,034,952 Immunome shares in Q1 2026, an estimated $151M.
Steven Cohen first reported a position in Immunome in Q2 2023 and held it in 11 quarters.
Steven Cohen's Immunome position peaked at $151M in Q4 2025.
201 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.